These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
225 related items for PubMed ID: 31077081
21. Digoxin use and clinical outcomes in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Guo Y, Kotalczyk A, Wang Y, Lip GYH. Europace; 2022 Jul 21; 24(7):1076-1083. PubMed ID: 35025995 [Abstract] [Full Text] [Related]
22. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Am J Cardiol; 2014 Aug 01; 114(3):401-6. PubMed ID: 24950677 [Abstract] [Full Text] [Related]
23. Impact of Digoxin on Mortality in Patients With Atrial Fibrillation Stratified by Heart Failure: Findings From Gulf Survey of Atrial Fibrillation Events in the Middle East. Al-Zakwani I, Panduranga P, Zubaid M, Sulaiman K, Rashed WA, Alsheikh-Ali AA, AlMahmeed W, Shehab A, Al Qudaimi A, Asaad N, Amin H. J Cardiovasc Pharmacol Ther; 2016 May 01; 21(3):273-9. PubMed ID: 26341119 [Abstract] [Full Text] [Related]
24. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Proietti M, Laroche C, Drozd M, Vijgen J, Cozma DC, Drozdz J, Maggioni AP, Boriani G, Lip GY, EORP-AF Investigators. Am Heart J; 2016 Nov 01; 181():83-91. PubMed ID: 27823697 [Abstract] [Full Text] [Related]
25. Whether Warfarin Therapy is Associated with Damage on Renal Function in Chinese Patients with Nonvalvular Atrial Fibrillation. Kong Y, Du X, Tang RB, Zhang T, Guo XY, Wu JH, Xia SJ, Ma CS. Chin Med J (Engl); 2016 May 20; 129(10):1135-9. PubMed ID: 27174319 [Abstract] [Full Text] [Related]
29. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Hallberg P, Lindbäck J, Lindahl B, Stenestrand U, Melhus H, RIKS-HIA group. Eur J Clin Pharmacol; 2007 Oct 20; 63(10):959-71. PubMed ID: 17684738 [Abstract] [Full Text] [Related]
30. Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study. Sessa M, Mascolo A, Andersen MP, Rosano G, Rossi F, Capuano A, Torp-Pedersen C. PLoS One; 2016 Oct 20; 11(7):e0160337. PubMed ID: 27467520 [Abstract] [Full Text] [Related]
31. Digoxin and Mortality in Patients With Atrial Fibrillation. Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L, ARISTOTLE Committees and Investigators. J Am Coll Cardiol; 2018 Mar 13; 71(10):1063-1074. PubMed ID: 29519345 [Abstract] [Full Text] [Related]
32. Predictive value of the heart rate reserve in patients with permanent atrial fibrillation treated according to a strict rate-control strategy. De Schryver N, Scavée C, Marchandise S, Pasquet A, de Meester C, le Polain de Waroux JB. Europace; 2014 Aug 13; 16(8):1125-30. PubMed ID: 24599938 [Abstract] [Full Text] [Related]
33. Real-World Comparison of Classes IC and III Antiarrhythmic Drugs as an Initial Rhythm Control Strategy in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study. Kipp R, Askari M, Fan J, Field ME, Turakhia MP. JACC Clin Electrophysiol; 2019 Feb 13; 5(2):231-241. PubMed ID: 30784696 [Abstract] [Full Text] [Related]
34. Body mass index and all-cause mortality in patients with atrial fibrillation: insights from the China atrial fibrillation registry study. Wang L, Du X, Dong JZ, Liu WN, Zhou YC, Li SN, Guo XY, Jiang CX, Yu RH, Sang CH, Tang RB, Long DY, Liu N, Bai R, Macle L, Ma CS. Clin Res Cardiol; 2019 Dec 13; 108(12):1371-1380. PubMed ID: 30953181 [Abstract] [Full Text] [Related]
35. Clinical outcomes in patients with atrial fibrillation treated with digoxin, according to the presence of heart failure: Insights from the MISOAC-AF trial. Botis M, Kartas A, Samaras A, Akrivos E, Vrana E, Liampas E, Papazoglou AS, Moysidis DV, Papanastasiou A, Baroutidou A, Karvounis H, Tzikas A, Parissis J, Drakos SG, Giannakoulas G. Hellenic J Cardiol; 2022 Dec 13; 68():25-32. PubMed ID: 36037999 [Abstract] [Full Text] [Related]
37. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. O'Meara E, Khairy P, Blanchet MC, de Denus S, Pedersen OD, Levesque S, Talajic M, Ducharme A, White M, Racine N, Rouleau JL, Tardif JC, Roy D, AF-CHF investigators. Circ Heart Fail; 2012 Sep 01; 5(5):586-93. PubMed ID: 22798522 [Abstract] [Full Text] [Related]
38. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Page RL, Connolly SJ, Crijns HJ, van Eickels M, Gaudin C, Torp-Pedersen C, Hohnloser SH, ATHENA Investigators. Am J Cardiol; 2011 Apr 01; 107(7):1019-22. PubMed ID: 21296333 [Abstract] [Full Text] [Related]
39. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, Mahaffey KW, Singer DE, Hylek EM, Go AS, Peterson ED, Piccini JP, Fonarow GC. J Am Coll Cardiol; 2017 Sep 12; 70(11):1325-1335. PubMed ID: 28882229 [Abstract] [Full Text] [Related]